Tumors and the danger model.

• Authors: Dariusz W Kowalczyk
• Languages of publication: EN

Abstracts

EN

This article reviews the evidence for the danger model in the context of immune response to tumors and the insufficiency of the immune system to eliminate tumor growth. Despite their potential immunogenicity tumors do not induce significant immune responses which could destroy malignant cells. According to the danger model, the immune surveillance system fails to detect tumor antigens because transformed cells do not send any danger signals which could activate dendritic cells and initiate an immune response. Instead, tumor cells or antigen presenting cells turn off the responding T cells and induce tolerance. The studies reviewed herein based on model tumor antigens, recombinant viral vectors and detection of tumor specific T cells by MHC/peptide tetramers underscore the critical role of tumor antigen presentation and the context in which it occurs. They indicate that antigen presentation only by activated but not by cancer or resting dendritic cells is necessary for the induction of immune responses to tumor antigens. It becomes apparent that the inability of dendritic cells to become activated provides a biological niche for tumor escape from immune destruction and seems to be a principal mechanism for the failure of tumor immune surveillance.

Keywords

EN

cancer; danger signal; dendritic cells

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 2
• Pages: 295-302

Dates

published

2002

received

2002-04-24

revised

2002-05-31

accepted

2002-06-02

Contributors

author

Dariusz W Kowalczyk

• Department of Cancer Immunology, K. Marcinkowski University School of Medical Sciences, GreatPoland Cancer Center, Garbary 15, 61-866 Poznań, Poland

References

• Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science.; 274: 94-6.
• Basu S, Binder RJ, Ramalingam T, Srivastava PK. (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity.; 14: 303-13.
• Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J. (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med.; 190: 1417-26.
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature.; 393: 478-80.
• Binder RJ, Han DK, Srivastava PK. (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol.; 1: 151-5.
• Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA. (2000) Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther.; 1: 225-35.
• Fuchs EJ, Matzinger P. (1992) B cells turn off virgin but not memory T cells. Science.; 258: 1156-9.
• Fuchs EJ, Matzinger P. (1996) Is cancer dangerous to the immune system? Semin Immunol.; 8: 271-80.
• Galluci S, Matzinger P. (2001) Danger signals: SOS to the immune system. Curr Opin Immunol.; 13: 114-9.
• He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC. (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology.; 270: 146-61.
• Janeway Jr CA. (1992) The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today.; 13: 11-6.
• Jooss K, Yang Y, Fisher KJ, Wilson JM. (1998) Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol.; 72: 4212-23.
• Kowalczyk DW, Ertl HC. (1999) Immune responses to DNA vaccines. Cell Mol Life Sci.; 55: 751-70.
• Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, Xiang ZQ, Giles-Davis W, Ertl HC. (2001) A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods.; 253: 163-75.
• Kowalczyk DW, Wlazlo AP, Giles-Davis W, Ertl HC. (2000) Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8(+) T cells. J Immunol Methods.; 241: 131-9.
• Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT. (2001) Papillomavirus- like particles induce acute activation of dendritic cells. J Immunol.; 166: 5346-55.
• Matzinger P. (1994) Tolerance, danger, and the extended family. Annu Rev Immunol.; 12: 991-1045.
• Matzinger P. (1998) An innate sense of danger. Semin Immunol.; 10: 399-415.
• Ridge JP, Di Rosa F, Matzinger P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature.; 393: 474-8
• Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. (1998) T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature.; 393: 480-3.
• Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A.; 95: 1178-83.
• Suto R, Srivastava PK. (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science.; 269: 1585-8.
• Udono H, Levey DL, Srivastava PK. (1994) Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A.; 91: 3077-81.
• Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science.; 259: 1745-9.
• Wu Y, Liu Y. (1994) Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T cell help in CD8+ T cell responses. Curr Biol.; 4: 499-505.
• Xiang ZQ, Yang Y, Wilson JM, Ertl HC. (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology.; 219: 220-7.